Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
ARESTIN®
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Interferon in relapsing-remitting multiple sclerosis.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Repurposing drugs for disease modification in multiple sclerosis
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.

Pages